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Abstract 
Background: Congenital fibrinogen disorders (CFDs) comprise about 10% of 
rare bleeding disorders (RBDs). CFDs are divided into two groups of 
quantitative (afibrinogenemia and hypofibrinogenemia) with autosomal 
recessive inheritance pattern, and qualitative (dysfibrinogenemia, 
hypodysfibrogenemia) disorders, mainly with autosomal dominant inheritance 
pattern. Sistan and Baluchestan Province in Iran, with its high rate of 
consanguineous marriages, has a high incidence of RBDs including CFD. In 
the current study, we report clinical manifestations of patients with CFDs.  
Materials and Methods: Twelve new Iranian patients from Sistan and 
Baluchestan province with different types of CFDs were selected for this study. 
Diagnosis of CFDs was based on clinical features and familial history followed 
by laboratory assessment by routine and specific coagulation tests including 
prothrombin time (PT) and activated partial time tests (APTT), as well as FI 
activity assay by Clauss method.  
Results: Out of 12 patients, 3 (25%) had afibrinogenemia, and 7 (58.3%) had 
hypofibrinogenemia, while 2 (16/7%) were suspected of having 
dysfibrinogenemia. Although umbilical cord bleeding (UCB) 9 (75%) was 
the most common clinical presentation among the study population, this 
feature was not observed among patients with dysfibrinogenemia. Hematoma 
(100%) was the most common presentation of patients with 
dysfibrinogenemia.  
Conclusion: Results of this study revealed that some clinical presentations are 
the diagnostic features of CFDs and can be used for precise and in-time 
diagnosis CFDs in conjunction with family history and laboratory findings.  
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Introduction 
Fibrinogen, or coagulation factor I (FI), is one 
of the acute-phase proteins that increases in response 
to stress and injury and is mainly secreted by 
hepatocytes as a 340 KDa glycoprotein. Plasma level 
of fibrinogen is 160-400 mg/dL with half time of about 
4 days (1, 2). Fibrinogen is a hexamer glycoprotein 
linked by 29 disulfide bonds; it is an asymmetric 
molecule with identical heterotrimers that, on each 
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side, consist of three chains including A (FGA), B 
(FGB) and γ (FGG) chains (3). Each of these chains is 
encoded by a separate gene with a length of 50 kbp on 
chromosome 4 (3, 4). Structurally, fibrinogen has a 
central domain (E) that encompasses the N-terminal of 
fibrinogen chains and connects to the peripheral 
domain (D) which contains the C-terminal of β and γ 
chains (5).  
Congenital fibrinogen disorders (CFD) are a 
group of coagulation disorders based on plasma 
fibrinogen level, divided into two types of quantitative, 
or type I, deficiencies including afibrinogenemia and 
hypofibrinogenemia, and qualitative, or type II, 
including dysfibrinogenemia and 
hypodysfibrinogenemia (3, 6). Afibrinogenemia is a 
rare bleeding disorder (RBD) with a variable bleeding 
tendency from mild to severe, life-threatening bleeding 
episodes (7, 8, 9). Patients with hypofibrinogenemia 
have a similar bleeding pattern, but their bleeding 
diatheses have a milder course (10). Type II fibrinogen 
deficiencies have variable bleeding tendency. In 
contrast to quantitative fibrinogen disorders, however, 
a considerable number of patients have thrombotic 
events. In spite of hypofibrinogenemia and 
afibrionogenemia, the amount of fibrinogen is normal 
in type II, whereas the function of fibrinogen antigen is 
reduced (11). CFDs are inherited mainly in autosomal 
recessive manner and therefore are more frequent in 
areas with a high rate of consanguineous marriage. 
Iran's high rate of consanguineous marriage results in 
a high rate of autosomal recessive disorders, including 
RBDs (3). In the current study, we report the clinical 
presentations of 12 new Iranian patients with CFD. 
Methods 
This study was conducted on 12 patients with 
CFD. All patients were selected from the Hemophilia 
Center of Zahedan. Initially, consent was obtained 
from all the participants and the study was approved by 
the medical ethics committee of Tehran University of 
Medical Science. At the beginning of the study, all 
patients were examined by a physician with expertise 
in bleeding disorders and all were interviewed by 
expert staff to complete a questionnaire that contains a 
number of questions about gender, age, race, as well as 
type and duration of treatment, therapeutic response, 
clinical manifestations and complications of treatment.  
All patients suspected of CFD were referred to 
the coagulation laboratory of the Iranian Blood 
Transfusion Organization (IBTO) of Zahedan for 
routine and specific coagulation tests. All patients were 
evaluated by routine coagulation tests including 
prothrombin time (PT) (normal range: 10.5-12.2 
seconds), activated partial thrombin time (APTT) 
(normal range: 24-38 seconds), thrombin time (TT), 
reptilase time (RT) (normal range:15-18 seconds, and 
19-21 seconds, respectively) (STA Compact 
automated coagulometer (Stago, Paris, France), 
bleeding time (BT) (normal range:3-8 minutes) (based 
on Ivy method), and platelet count (normal 
range:150,000- 450,000) (Sysmex Kx-21 
Haematology Analyzer, Kobe, Japan). Patients with 
prolonged PT, PTT, TT and/or RT were candidate for 
fibrinogen assay by the Clauss method (normal range: 
160-400 mg/dL). Finally, results were reported as 
mean ± standard deviation (SD) for quantitative 
variables and percentages for categorical variables. 
Results 
The study population included 6 (50%) women 
and 6 (50%) men; the mean age of the patients and the 
mean age of diagnosis were 13.2±4 and 4.2±2 years 
old, respectively. Out of 12 patients, 7 (58%) were born 
into a consanguineous marriage. Routine coagulation 
tests including PT, PTT and TT were increased in 
afibrinogenemia and hypofibrinogenemia patients 
while in patients suspected of dysfibrinogenemia these 
assays were relatively increased. 
Three patients (25%) had afibrinogenemia, 7 
(58.3%) had hypofibrinogenemia while 2 patients 
(16.7%) were suspected to have dysfibrinogenemia, 
based on clinical features and laboratory assays. The 
mean level of functional fibrinogen activity in 
afibrinogenemia and hypofibrinogenemia patients was 
<10mg/dl and 18mg/dl respectively while in patients 
suspected of dysfibrinogenemia the mean level of 
fibrinogen activity was 109.5mg/dl (Table 1).  
Umbilical cord bleeding was the most common 
presentation leading to CFD diagnosis in all patients 
with afibrinogenemia; it occurred in 6 patients (85.7%) 
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with hypofibrinogenemia. Hematoma was seen in all 
patients with dysfibrinogenemia while observed in 
only one patient with hypofibrinogenemia. 
Miscarriage was observed in only one patient with 
hypofibrinogenemia (Table 1). 
Discussion 
Sistan and Baluchestan Province, in the southeast of 
Iran, has high rate of RBDs, specifically factor XIII 
(FXIII) deficiency. The estimated incidence of 
afibrinogenemia, the most severe form of CFD, is one 
per one million in the general population, while the 
prevalence of other CFDs is higher. In southeast Iran, 
with a population of 2,700,000, 12 patients were 
diagnosed with CFDs. According to our last survey in 
2011, CFDs comprise 3.1% of all RBDs in southeast 
Iran (Table 2) (12).  
Out of 12 patients with CFDs, 3, 7, and 2 patients had 
afibrinogenemia, hypofibrinogenemia, and 
dysfibrinogenemia respectively, therefore the 
incidence of CFDs is higher in southeast of Iran 
compared to the general worldwide prevalence of this 
disorder. Afibrinogenemia is the most severe form of 
CFDs and, in the current study, umbilical cord bleeding 
was the first clinical finding among all three patients 
with afibrinogenemia. According to the study by 
Peyvandi et al, umbilical cord bleeding is a grade III 
(life-threatening) bleeding that requires immediate 
medical intervention. Umbilical cord bleeding is the 
most common clinical presentation among patients 
with FXIII deficiency (FXIIID). Our recent study on a 
large number of FXIIID patients found that umbilical 
cord bleeding is one of their most common causes of 
death. Therefore, in areas such as Sistan and 
Baluchestan Province, with high rates of RBDs, 
umbilical cord bleeding should be considered 
diagnostic of FXIIID and afibrinogenemia, requiring 
immediate medical intervention. It previously was 
reported that patients with hypofibrinogenemia had 
milder presentations, but among our patients, umbilical 
cord bleeding was the most common presentation, seen 
among all seven patients (85.7%). Severe clinical 
presentations such as menorrhagia (40%) and 
hematoma (12%) were seen among patients with 
hypofibrinogenemia in other studies but in current 
study their presentations were more severe than usually 
reported (10). Patients with inherited 
dysfibrinogenemia are usually asymptomatic; 
nonetheless bleeding diathesis, thromboembolic 
complications, or both, were seen in these patients 
(11). Clinical presentations of patients with 
dysfibrinogenemia were severe, most common among 
them being hematoma. Although thrombotic diathesis 
can be observed among patients with CFDs, especially 
dysfibrinogenemia, none of our patients experienced 







UCB* Hematoma Miscarriage 
Afibrinogenemia 25% <10 mg/dl 100% _ _ 
Hypofibrinogenemia 58/3% <18 mg/dl 85/7% 14/2% 14/2% 
Dysfibrinogenemia 16/7% 109/5 mg/dl _ 100% _ 
 
*UCB: Umbilical Cord Bleeding 
Table 2: Congenital Fibrinogen Disorders in a Province of Iran, Italy and Worldwide 
Factor I                                                     II V V-VIII   VII    X    XI      XIII 
Worldwide 10 2 10     3      23 9     37   6 
Italy 8 5 10     9      25 8     24 11 
Sistan& Baluchestan* 3.1 2 5.8    0.3      6.2 2.8  0.3       79.5 
*According to total number of 292 patients with RBD in the province. 
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this diathesis.  
It seems, therefore, that clinical features can be 
used as diagnostic clues for precise and in-time 
diagnosis of CFDs, especially umbilical cord bleeding, 
which was the first clinical finding in 9 (75%) of our 
patients. 
Conclusion 
Results of this study revealed that some clinical 
presentations are the diagnostic features of CFDs and 
can be used for precise and in-time diagnosis CFDs in 
conjunction with family history and laboratory 
findings. 
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